The growth of the genomics market is driven by the rising prevalence of genetic disorders and cancer, along with increasing awareness of early disease detection through genetic testing.
WILMINGTON, Del., Feb. 11, 2026 /PRNewswire/ — Allied Market Research published a report, titled, “Genomics Market by Product (Consumables and Reagent, Services, Instruments and Systems and Software), Technology (Sequencing, PCR, Flow Cytometry, Microarray and Others), Application (Functional Genomics, Epigenomics, Pathway Analysis, Biomarker Discovery and Others), and End User (Clinical Research, Academic and Government Institutions, Hospitals and Clinics, Pharmaceutical and Biotechnology Companies and Others): Global Opportunity Analysis and Industry Forecast, 2024-2033″. According to the report, the genomics market was valued at $33.2 billion in 2023, and is estimated to reach $97.1 billion by 2033, growing at a CAGR of 11.5% from 2024 to 2033.
Key Factors Supporting Growth of the Genomics Market
Expanding applications in precision medicine and drug discovery further accelerate market adoption. However, high sequencing costs and concerns related to data privacy and reimbursement policies may restrain growth. Meanwhile, technological advancements and expanding healthcare and research infrastructure in emerging economies present significant opportunities for market expansion in the coming years.
Request Sample of the Report on Global Genomics Market 2033 – https://www.alliedmarketresearch.com/request-sample/5474
The consumables and reagents segment generated the highest revenue in 2023
By product, the consumables and reagents segment accounted for the largest market share in 2023. Library preparation kits, sequencing reagents, and PCR consumables are essential for routine genomic workflows. Their recurring usage in laboratories, diagnostic centers, and pharmaceutical research drives consistent demand, supporting revenue growth compared to instruments, systems, software, and services.
The sequencing segment generated the highest revenue in 2023
By technology, the sequencing segment accounted for the highest revenue in the genomics market in 2023. Next-generation sequencing (NGS) is widely adopted due to its high accuracy, scalability, and declining cost per genome. It plays a critical role in oncology profiling, rare disease diagnosis, population genomics, and drug discovery. Continuous advancements in high-throughput platforms and bioinformatics tools further strengthened its market position across research and clinical applications.
The biomarker discovery segment generated significant revenue in 2023
By application, biomarker discovery held a substantial share of the genomics market in 2023. The growing focus on precision medicine and targeted therapies increased the need to identify reliable genetic biomarkers for disease diagnosis and treatment optimization. Functional genomics and epigenomics also contributed notably due to expanding molecular and gene expression research.
Want to Explore More, Connect to our Analyst – https://www.alliedmarketresearch.com/connect-to-analyst/5474
The pharmaceutical and biotechnology companies segment generated the highest revenue in 2023
By end user, pharmaceutical and biotechnology companies accounted for the largest revenue share in 2023. These companies extensively utilize genomic technologies for drug discovery, target identification, and clinical trial optimization. Academic institutions, government organizations, hospitals, and clinics also contributed significantly to overall market demand.
Regional Outlook
Region wise, North America dominated the genomics market in 2023, supported by strong research funding, advanced healthcare infrastructure, and the presence of key industry players. For instance, in 2021 a significant investment in genomics research was made by the U.S. government, which announced a $1.7 billion funding initiative to enhance genomic sequencing capabilities across the U.S. The investment included an initial distribution of $240 million to states and other jurisdictions, the establishment of six Centers of Excellence in Genomic Epidemiology with a $400 million budget, and $300 million dedicated to developing a National Bioinformatics Infrastructure to support bioinformatics throughout the U.S. public health system. Europe held a significant share, while Asia-Pacific emerged as a rapidly growing region driven by increasing healthcare investments and expanding genomics research initiatives.
Key Players

- Color Genomics, Inc
- BGI Genomics
- Agilent Technologies
- Bio-Rad Laboratories, Inc
- Danaher Corporation
- Eppendorf AG
- Eurofins Scientific
- F. Hoffmann-La Roche Ltd.
- GE Healthcare
- Illumina, Inc.

Source link
















Leave a Reply